Frailty and Gallbladder Drainage
The study documents technical feasibility in a narrowly selected high-risk population, while its size, design, exclusions, and one early death sharply limit broader conclusions.
> Research explainer: This briefing examines verified primary research published 60 days before the briefing date. It is not a same-day research update and does not provide medical advice.
Evidence
The source reports a single-center, retrospective pilot study of 10 extremely elderly and frail patients treated for acute cholecystitis at HITO Medical Center in Japan. Procedures occurred from September 2025 through February 2026, after Japanese reimbursement approval for the device. The cohort had a median age of 90 years and a median Clinical Frailty Scale score of 7. Eligibility required acute cholecystitis, high surgical risk defined by Charlson Comorbidity Index at least 6 and/or ASA physical-status score at least 3, and multidisciplinary agreement that cholecystectomy was inappropriate. [pmid:42338918]
All 10 patients underwent transduodenal endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with an electrocautery-enhanced 10-mm lumen-apposing metal stent (LAMS). The procedure involved identifying an avascular puncture path by color Doppler, deploying the stent between the gallbladder and duodenal lumen, and confirming drainage and placement. The report states that all procedures were performed by one endoscopist certified to use the Hot AXIOS system, with intravenous propofol sedation, supplemental oxygen, and continuous cardiopulmonary monitoring. [pmid:42338918]
Technical success, defined as deployment with adequate apposition confirmed by endoscopic ultrasound and/or fluoroscopy, was achieved in all 10 patients. Clinical success was achieved in 9 of 10 patients, or 90%. One patient with Grade III cholecystitis complicated by severe pneumonia and heart failure died on postoperative day 1 before clinical assessment. Median stent-deployment time was 3.5 minutes, while median total procedure time was 16 minutes. [pmid:42338918]
The investigators also report that cholecystoscopy through the 10-mm stent using a slim endoscope was feasible when required. Their stated post-procedure approach included monitoring symptom resolution and inflammatory markers. For selected patients whose condition and preferences supported further intervention, the team considered follow-up cholecystoscopy for gallstone assessment and removal. The report notes uncertainty about long-term outcomes with permanent LAMS placement and says elective replacement with a plastic stent was offered after discussion with patients and families. [pmid:42338918]
Analysis — Scope and Interpretation
This source is relevant to a Heart & Lungs briefing chiefly because it documents a procedure performed in a population with substantial frailty and comorbidity, including one reported death in a patient with severe pneumonia and heart failure. It does not evaluate a heart or lung treatment, and it cannot show whether cardiopulmonary disease altered procedural outcomes. The report supports a narrower interpretation: in 10 selected patients considered inappropriate candidates for cholecystectomy, transduodenal EUS-GBD with an electrocautery-enhanced 10-mm LAMS was technically feasible at this center. [pmid:42338918]
The 100% technical-success figure and 90% clinical-success figure describe observed outcomes in this small case series, not expected results for comparable patients elsewhere. The study’s practical details matter: a single certified endoscopist performed every procedure, the center used one device and approach, and patient selection included multidisciplinary agreement and anatomical, severity, endoscopic, and radiologic assessment. Those conditions may have contributed to the observed results and are not a comparison against surgery, percutaneous drainage, or endoscopic transpapillary drainage. [pmid:42338918]
The early death is especially important for interpretation. The paper reports that clinical assessment could not occur before postoperative day 1 in a patient with severe pneumonia and heart failure; it does not establish that the procedure caused the death. At the same time, the event prevents any uncomplicated reading of aggregate success rates. The authors themselves characterize the findings as preliminary, state that larger studies are required, and emphasize careful patient selection. [pmid:42338918]
Limitations
This was a retrospective, single-center study of only 10 consecutive patients, with no concurrent control group and no randomized allocation. It therefore cannot establish comparative effectiveness, comparative safety, or causal explanations for the observed outcomes. The procedures covered an initial post-reimbursement period in Japan, and all were conducted by one certified operator, limiting transferability to other settings. [pmid:42338918]
The inclusion criteria focused on patients with acute cholecystitis at high surgical risk who were judged unsuitable for cholecystectomy. Patients with suspected gangrenous or perforated cholecystitis were excluded because LAMS use was not permitted for those conditions under the cited Japanese guidance. Findings should not be generalized to those excluded presentations or to broader acute-cholecystitis populations. [pmid:42338918]
Follow-up and long-term device management remain limited in the supplied report. The authors explicitly note uncertainty about permanent LAMS placement and call for validation in larger studies. The source contains no evidence sufficient for patient-specific conclusions, treatment recommendations, or predictions about cardiopulmonary outcomes. [pmid:42338918]